ReviewJournal of the National Comprehensive Cancer Network : JNCCN2021
Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor.
Review in Journal of the National Comprehensive Cancer Network : JNCCN, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 46 citations in OpenAlex.
- Long-term outcomes and patterns of relapse in patients with bilateral Wilms tumor or bilaterally predisposed unilateral Wilms tumor, a report from the COG AREN0534 study.International journal of cancer · 2024Trial
- Trial
- Actinomycin Analogs From Streptomyces polyantibioticus S4D258: Structural Elucidation and Antiproliferative Activity Against Triple-Negative Breast Cancer.Chemistry & biodiversity · 2026Article
- NCBP1 promotes the malignant progression of Wilms' tumor through stabilization of KPNA2 mRNA.Cancer gene therapy · 2026Article
- Dual metabolic intervention nanoplatform co-delivering BAY-876 and L-cystine for Wilms tumor therapy via disulfidptosis-associated cytoskeletal collapse.Journal of nanobiotechnology · 2026Article
- Multi-omics analysis identifies stemness-driven molecular subtypes, prognostic signature, epigenetic target APCDD1, and drug candidate Leflunomide in Wilms tumor.Frontiers in oncology · 2026Article
- Case Report: Bilateral Wilms tumor with TP53 mutation: a case-based review of clinical challenges.Frontiers in surgery · 2026Article
- Expanding Role of Nephron-Sparing Surgery in Non-syndromic Unilateral Unifocal Wilm's Tumor-Our Experience and Review of Literature.Journal of kidney cancer and VHL · 2026Article
- Analysis of prognostic factors and development of a predictive model following radical nephrectomy for Wilms tumor in children.Oncology letters · 2025Article
- Updated favourable-histology Wilms tumour risk stratification: rationale for future Children's Oncology Group clinical trials.Nature reviews. Urology · 2025Review
- Prevalence and Determinants of Impaired Bone Mineral Density and Fractures in the First National Dutch Wilms Tumor Survivor Cohort, a National DCCSS-LATER Study.Cancer medicine · 2025Article
- Data set for reporting paediatric renal tumours: recommendations from the international collaboration on cancer reporting (ICCR).Histopathology · 2025Review
- Predictors and course of hypertension in Wilms tumour patients: a retrospective observational cohort study.BMJ paediatrics open · 2025Observational
- Bilateral Wilms Tumour: Is Neoadjuvant Doxorubicin Necessary?Children (Basel, Switzerland) · 2025Review
- The signature based on interleukin family and receptors identified IL19 and IL20RA in promoting nephroblastoma progression through STAT3 pathway.Scientific reports · 2025Article
- Bilateral Wilms tumor with anaplasia: A report from the Children's Oncology Group Study AREN0534.Pediatric blood & cancer · 2024Article
- The impact of the route to diagnosis in nephroblastoma.Cancer medicine · 2024Article
- Article
- Fetal Wilm's tumor detection preceding the development of isolated lateralized overgrowth of the limb: a case report and review of literature.Frontiers in pediatrics · 2024Article
- Late Health Outcomes Among Survivors of Wilms Tumor Diagnosed Over Three Decades: A Report From the Childhood Cancer Survivor Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors at 12 institutions in 2 countries.
Funding
Abstract
Refinements in surgery, radiation therapy, and chemotherapy since the mid-20th century have resulted in a survival rate exceeding 90% for patients with Wilms tumor (WT). Although this figure is remarkable, a significant proportion of patients continue to have event-free survival (EFS) estimates of <75%, and nearly 25% of survivors experience severe chronic medical conditions. The first-generation Children's Oncology Group (COG) renal tumor trials (AREN '0'), which opened to enrollment in 2006, focused on augmenting treatment regimens for WT subgroups with predicted EFS <75% to 80%, including those with the adverse prognostic marker of combined loss of heterozygosity (LOH) at chromosomes 1p/16q, pulmonary metastasis with incomplete lung nodule response after 6 weeks of chemotherapy, bilateral disease, and anaplastic histology. Conversely, therapy was reduced for patient subgroups with good outcomes and potential for long-term toxicity, such as those with lung metastasis with complete lung nodule response after 6 weeks of chemotherapy. This article summarizes the key findings of the first-generation COG renal tumor studies and their implications for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.